ムーンレイク・イミュノセラピューティクス
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.98 | $0 | -$66M |
| 2025 Q4 | -0.93 | $0 | -$59M |
| 2025 Q3 | -1.10 | $0 | -$45M |
| 2025 Q2 | -0.87 | $0 | -$55M |
| 2025 Q1 | -0.63 | $0 | -$38M |
| 2024 Q4 | -0.72 | $0 | -$49M |
| 2024 Q3 |
| -0.56 |
| $0 |
| -$25M |
| 2024 Q2 | -0.39 | $0 | -$28M |